Drug Trial Radar · NCT06308978
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
244
Planned (sponsor's estimate)
Start
Mar 28, 2024
Primary completion
Sep 30, 2027
Study completion Sep 30, 2042
Sponsor
- Lead sponsor
- Fate TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Conditions
- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myositis (IIM)
- Systemic Sclerosis (SSc)
- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis
Interventions
FT819Drug
FT819 will be administered as intravenous (IV) infusion at planned dose levels.
FludarabineDrug
Fludarabine will be administered as an IV infusion at planned dose levels.
CyclophosphamideDrug
Cyclophosphamide will be administered as an IV infusion at planned dose levels.
BendamustineDrug
Bendamustine will be administered as an IV infusion at planned dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to approximately 2 years
- Number of participants with serious TEAEsTime frame: Up to approximately 2 years
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to approximately 29 days
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
Wallace Rheumatic Center
Beverly Hills, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
University of California Irvine
Irvine, California · Recruiting
Children's Hospital Los Angeles Division Of Rheumatology
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
University of Louisville
Louisville, Kentucky · Recruiting
University of Minnesota Medical School
Minneapolis, Minnesota · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Montefiore Medical Center
New York, New York · Recruiting
Duke University Health System
Durham, North Carolina · Recruiting
MetroHealth
Cleveland, Ohio · Recruiting
University of Oklahoma
Oklahoma City, Oklahoma · Recruiting
Jefferson Einstein Hospital Philadelphia
Philadelphia, Pennsylvania · Recruiting
Regional One Health
Memphis, Tennessee · Recruiting
Hôpital La Pitié Salpêtrière
Paris, France · Recruiting
Uppsala University
Uppsala, Uppland, Sweden · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
University College of London Hospitals NHS Trust (UCLH)
London, United Kingdom · Recruiting
Manchester University NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.